查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1982764

全球脑膜炎双球菌疫苗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Meningococcal Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计脑膜炎双球菌疫苗市场将从 2025 年的 29.6 亿美元成长到 2034 年的 51.6 亿美元，2026 年至 2034 年的复合年增长率为 6.39%。

由于人们加强了预防脑膜炎双球菌感染疾病，全球脑膜炎双球菌疫苗市场经历了显着成长。脑膜炎球菌感染是严重的细菌感染，可引起病菌感染和血液感染疾病。免疫接种计画在降低疾病的发生率方面发挥了至关重要的作用，尤其是在婴幼儿、青少年和高风险族群中。

脑膜炎球菌疫苗市场的主要驱动因素包括公共卫生工作的加强和免疫接种计划的扩大。世界各国政府和医疗机构都在积极进行疫苗宣传活动，旨在预防疫情爆发并保护弱势族群。此外，疫苗研发的进步也推动了更有效、保护更广泛的疫苗的研发。

随着全球医疗卫生体系加强疾病预防策略，脑膜炎双球菌疫苗市场预计将会扩大。疫苗技术的持续研究以及人们对疫苗接种益处的认识不断提高，有望促进疫苗接种率的提升。此外，发展中地区医疗卫生基础设施的不断完善，预计也将改善脑膜炎双球菌疫苗的可近性。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球脑膜炎双球菌疫苗市场：按类型划分

  • 市场分析、洞察与预测
  • 二价
  • 四价
  • 其他的

第五章 全球脑膜炎双球菌疫苗市场：依品牌划分

  • 市场分析、洞察与预测
  • 梅纳克特拉
  • Membeo
  • 尼门里克斯
  • 托尔门巴
  • 维克塞洛
  • 其他的

第六章 全球脑膜炎双球菌疫苗市场：依年龄组别划分

  • 市场分析、洞察与预测
  • 婴幼儿（0-2岁）
  • 儿童及成人（2岁以上）

第七章 全球脑膜炎双球菌疫苗市场：依血清型划分

  • 市场分析、洞察与预测
  • A型血清型
  • B型血清型
  • C型血清型
  • 血清型 W-135
  • Y型血清型

第八章 全球脑膜炎双球菌疫苗市场：依销售管道划分

  • 市场分析、洞察与预测
  • 私人的
  • 一般的

第九章 全球脑膜炎双球菌疫苗市场：按地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十一章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Pfizer Inc
    • Sanofi
    • Serum Institute Of India Ltd
    • GSK Plc
    • Merck & Co. Inc
    • Walvax Biotechnology Co. Ltd
    • Chongqing Zhifei Biological Products Co. Ltd
    • Baxter International
    • CSL Limited
    • Bavarian Nordic Incepta Vaccine Ltd
    • Sinovac Biotech Ltd
    • Novartis
    • Panacea Biotec Ltd
简介目录
Product Code: VMR11212373

The Meningococcal Vaccine Market size is expected to reach USD 5.16 Billion in 2034 from USD 2.96 Billion (2025) growing at a CAGR of 6.39% during 2026-2034.

The global meningococcal vaccine market has experienced significant growth due to increasing efforts to prevent meningococcal disease, a serious bacterial infection that can cause meningitis and bloodstream infections. Vaccination programs have played a crucial role in reducing the incidence of this disease, particularly among infants, adolescents, and individuals at higher risk.

Key drivers of the meningococcal vaccine market include growing public health initiatives and expanding immunization programs. Governments and healthcare organizations are promoting vaccination campaigns to prevent outbreaks and protect vulnerable populations. Additionally, advancements in vaccine research have led to the development of more effective and broader protection vaccines.

In the future, the meningococcal vaccine market is expected to expand as global healthcare systems strengthen disease prevention strategies. Continued research in vaccine technology and increasing awareness about immunization benefits may support higher vaccination coverage. Furthermore, expanding healthcare infrastructure in developing regions will likely increase access to meningococcal vaccines.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Bivalent
  • Quadrivalent
  • Others

By Brand

  • Menactra
  • Menveo
  • Nimenrix
  • Trumenba
  • Bexsero
  • Others

By Age Group

  • Infants (0 to 2 years)
  • Children And Adults (2 years & above)

By Serotype

  • Serotype A
  • Serotype B
  • Serotype C
  • Serotype W-135
  • Serotype Y

By Sales Channel

  • Private
  • Public

COMPANIES PROFILED

  • Pfizer Inc, Sanofi, Serum Institute of India Ltd, GSK plc, Merck Co Inc, Walvax Biotechnology Co Ltd, Chongqing Zhifei Biological Products Co Ltd, Baxter International, CSL Limited, Bavarian Nordic Incepta Vaccine Ltd, Sinovac Biotech Ltd, Novartis, Panacea Biotec Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Bivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY BRAND 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Brand
  • 5.2. Menactra Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Menveo Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Nimenrix Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.5. Trumenba Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.6. Bexsero Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Age Group
  • 6.2. Infants (0 to 2 years) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Children And Adults (2 years & above) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY SEROTYPE 2022-2034 (USD MN and Million Doses)

  • 7.1. Market Analysis, Insights and Forecast Serotype
  • 7.2. Serotype A Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.3. Serotype B Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.4. Serotype C Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.5. Serotype W-135 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.6. Serotype Y Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY SALES CHANNEL 2022-2034 (USD MN and Million Doses)

  • 8.1. Market Analysis, Insights and Forecast Sales Channel
  • 8.2. Private Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.3. Public Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.2.1 By Type
    • 9.2.2 By Brand
    • 9.2.3 By Age Group
    • 9.2.4 By Serotype
    • 9.2.5 By Sales Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.3.1 By Type
    • 9.3.2 By Brand
    • 9.3.3 By Age Group
    • 9.3.4 By Serotype
    • 9.3.5 By Sales Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.4.1 By Type
    • 9.4.2 By Brand
    • 9.4.3 By Age Group
    • 9.4.4 By Serotype
    • 9.4.5 By Sales Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.5.1 By Type
    • 9.5.2 By Brand
    • 9.5.3 By Age Group
    • 9.5.4 By Serotype
    • 9.5.5 By Sales Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.6.1 By Type
    • 9.6.2 By Brand
    • 9.6.3 By Age Group
    • 9.6.4 By Serotype
    • 9.6.5 By Sales Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL MENINGOCOCCAL VACCINE INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Pfizer Inc
    • 11.2.2 Sanofi
    • 11.2.3 Serum Institute Of India Ltd
    • 11.2.4 GSK Plc
    • 11.2.5 Merck & Co. Inc
    • 11.2.6 Walvax Biotechnology Co. Ltd
    • 11.2.7 Chongqing Zhifei Biological Products Co. Ltd
    • 11.2.8 Baxter International
    • 11.2.9 CSL Limited
    • 11.2.10 Bavarian Nordic Incepta Vaccine Ltd
    • 11.2.11 Sinovac Biotech Ltd
    • 11.2.12 Novartis
    • 11.2.13 Panacea Biotec Ltd